Edition:
United Kingdom

Dova Pharmaceuticals Inc (DOVA.OQ)

DOVA.OQ on NASDAQ Stock Exchange Global Market

34.71USD
20 Feb 2018
Change (% chg)

$0.03 (+0.09%)
Prev Close
$34.68
Open
$34.50
Day's High
$35.52
Day's Low
$34.24
Volume
18,807
Avg. Vol
32,898
52-wk High
$35.52
52-wk Low
$16.98

Select another date:

Tue, Feb 20 2018

BRIEF-Dova Pharmaceuticals Announces Proposed Offering Of Common Stock

* DOVA PHARMACEUTICALS, INC. ANNOUNCES PROPOSED OFFERING OF COMMON STOCK

BRIEF-Dova Pharma Files For Offering Of Up To 2.5 Mln Shares

* DOVA PHARMACEUTICALS INC FILES FOR OFFERING OF UP TO 2.5 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING Source text for Eikon: (http://bit.ly/2FgTI9o) Further company coverage:

BRIEF-Dova Pharmaceuticals Reports Qtrly Loss Per Share $‍0.36​

* DOVA PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 OPERATING AND FINANCIAL RESULTS

BRIEF-Dova Pharmaceuticals Announces Appointment Of Mark W. Hahn As Chief Financial Officer

* DOVA PHARMACEUTICALS ANNOUNCES THE APPOINTMENT OF MARK W. HAHN AS CHIEF FINANCIAL OFFICER

BRIEF-Dova Pharmaceuticals Inc - Supplemental NDA For Avatrombopag in ITP To Be Submitted In Second Half Of 2018

* DOVA PHARMACEUTICALS PROVIDES UPDATE ON DEVELOPMENT STRATEGY FOR AVATROMBOPAG IN IMMUNE THROMBOCYTOPENIC PURPURA (ITP) AND CHEMOTHERAPY-INDUCED THROMBOCYTOPENIA (CIT)

BRIEF-Dova Pharmaceuticals Announces FDA Acceptance Of The Avatrombopag New Drug Application With Priority Review

* DOVA PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE AVATROMBOPAG NEW DRUG APPLICATION (NDA) WITH PRIORITY REVIEW

BRIEF-Dova Pharmaceuticals reports third quarter results

* Dova Pharmaceuticals reports third quarter 2017 operating and financial results

BRIEF-Dova Pharmaceuticals announces New Drug Application submission to FDA

* Dova Pharmaceuticals announces New Drug Application submission to FDA for avatrombopag, a second generation thrombopoietin receptor agonist

Select another date: